Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE-004: CURB Trial for Oligoprogressive Metastatic Disease
NCT03808662Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2019
- Primary completion
- Jan 2027
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and breast cancer (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression Free Survival at 52 weeks. Started Jan 2019; status: active, not recruiting.
02
Conditions
triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT03808662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808662.